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Recently, many studies have evaluated HPV vaccine safety and adverse effects. Two vaccines
have been recently evaluated in randomized controlled trials: the bivalent vaccine for HPV
16 and 18 (Cervarix, GlaxoSmithKline Biologicals, Rixensart, Belgium) and the quadrivalent
vaccine  for HPV 6, 11, 16, and 18 (Gardasil, Merck and Co., Inc., Whitehouse Station, NJ). We
have  performed a systematic review of all randomized controlled trials in which HPV vac-
cines  were compared with placebo regarding safety, tolerability and adverse effects. Studies
were  searched up to March 2013 in the databases: Pubmed, Embase, Scielo and Cancerlit.
Odds  Ratios (OR) of most incident adverse effects were obtained. Twelve reports, involv-
ing  29,540 subjects, were included. In the HPV 16/18 group, the most frequently reported
events  related to the vaccine were pain (OR 3.29; 95% CI: 3.00–3.60), swelling (OR 3.14; 95%
CI:  2.79–3.53) and redness (OR 2.41; 95% CI: 2.17–2.68). For the HPV 6/11/16/18 group the events
were  pain (OR 2.88; 95% CI: 2.42–3.43) and swelling (OR 2.65; 95% CI: 2.0–3.44). Concerning the
HPV  16/18 vaccine, pain was the most common outcome detected. These effects can be due
to  a possible VLP-related inﬂammation process. Fatigue was the most relevant general effect
observed  followed by fever, gastrointestinal symptoms, and headache. In the HPV 6/11/16/18
group,  only general symptoms, pain and swelling were observed. Pain and swelling were  the
most frequent. Comparing HPV 16/18 to HPV 6/11/16/18 vaccines, the former presented moreadverse  effects, perhaps because there are many more trials evaluating the bivalent vaccine.
Other  studies are needed to clarify this issue.
is  necessary to develop cervical cancer. This has led to
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an  increase in effectiveness of screening for cervical cancer
using  Pap smears and the development of primary prevention
through  the use of prophylactic vaccines against HPV.5–11
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2494 papers
identified
68 papers met
search criteria
12 papers
included
2426 of which were excluded:
2267 after review of the title and
159 after review of the abstract.
56 of which were excluded:
46 papers were not considered
of adequate methodological quality;
nine repeated studies (they were
present in two databases at the
same time); two studies used the
same population.
Fig. 1 – Inclusion and exclusion of trials in study selection.652  b r a z j i n f e c t d 
The prophylactic vaccine stimulates the development of
the  humoral immune response, which occurs after contact
with  the “virus-like particles” (VLPs), which are non-infectious
structures and simulate a natural HPV infection. The two
oncogenic  types included in both vaccines are HPV 16 and
18,  responsible for at least 70% of the cases of cervical can-
cer  worldwide. In the case of the quadrivalent vaccine, it also
included  two non-oncogenic types of HPV, 6 and 11, responsi-
ble  for approximately 90% of cases of anogenital condylomata
acuminata.12
Safety and tolerability of both vaccines have been evalu-
ated  extensively with similar proﬁles in the vaccinated and
control  groups, irrespective of age or ethnicity.1 Studies about
safety  assessment indicated that local and systemic injection-
related  symptoms were  generally mild. Serious adverse effects
(AE)  that are considered to be vaccine related are rare and
similar  to other vaccine types.13,14
Studies indicate that the most common AE is injection-
related local reaction, such as pain, swelling and erythema
with  a rate of 95% of light to moderate intensity.15,16 Regarding
systemic symptoms, fever, nausea, vomiting, dizziness, myal-
gia  and diarrhea were  reported.15,17,18 Severe AE, such as
severe headache with hypertension, gastroenteritis and bron-
chospasm,  were  described in 0.5%.15 There are more  data
available of AE associated with the quadrivalent vaccine than
the  bivalent vaccine; however, the major AE for the latter vac-
cine  is also in the injection-related local pain (78%).15
Both HPV vaccines are classiﬁed as Pregnancy Category B
by  the FDA. Therefore, the vaccine is not recommended for
pregnant  women, because there are not enough data to ensure
safety  to the fetus.19,20
Studies have also demonstrated efﬁcacy and safety of the
vaccine  in heterosexual and homosexual men.21 This is impor-
tant  as HPV also causes disease in men.
The safety proﬁles of HPV vaccines have been conﬁrmed
by  their huge use worldwide, and they has been included
in  immunization schedules of 28 countries. So far, there has
not  been any absolute contraindication for the use of these
vaccines.15 The vaccines are well tolerated and the number of
systemic  AE, serious AE, and discontinuations due to a seri-
ous  event are similar between the two vaccines and control
groups.19
The purpose of this study was  to evaluate safety and AE of
HPV  vaccines.
Materials  and  methods
This study adhered to PRISMA guidelines.22 As a secondary
study, no Institutional Review Board approval was  required.
Inclusion  criteria
Studies meeting the following criteria were included: (1)
double-blind randomized clinical trials evaluating safety and
adverse  effects of human papillomavirus (HPV) vaccines
(against 16/18 and/or 6/11/16/18 serotypes); (2) studied sub-
jects  were  older than nine years old; (3) exclusion of study
participants with high risk of contracting, such as female sexRCTs,  randomized controlled trials.
workers and women who were sexual partners of HIV-infected
men,  and (4) exclusion of pregnant women.
Search  and  selection  of  literature
The studies were  identiﬁed by a wide literature search of
databases  (PubMed, Embase, Scielo and Cancerlit) following
medical  subject heading terms and/or text words: (vaccines
OR  vaccination) AND (randomized controlled trial) OR (con-
trolled  clinical trial) OR (randomized controlled trials) OR
(random  location) OR (double blind method) OR (single blind
method)  OR (clinical trial) AND (Human papillomavirus) OR
(HPV)  OR (papilloma virus) OR (papillomavir*). Reference lists
of  the identiﬁed publications for additional pertinent studies
were  reviewed. No language restrictions were  imposed. Three
researchers  (AGM, HMR and RNC) searched for articles pub-
lished  up to March 2013.
Study identiﬁcation and selection is illustrated in the ﬂow
diagram  in Fig. 1. After searching the databases, 2494 poten-
tially  relevant papers were identiﬁed, of which 2426 were
excluded: 2267 after reviewing the title, and 159 after review-
ing  the abstract. Reviews were done by AGM, HMR, and RNC;
disagreements were  solved by a fourth reviewer (AKG). Thus,
68  papers met  the criteria and were reviewed in full. There
were  no articles in languages other than English, which,
based  on the abstract review, met  the inclusion criteria. After
full  review, 46 papers were not considered to have adequate
methodological quality according to the Jadad Scale.23 Finally,
nine  repeated studies were  found (they were  present in two
databases  at the same time), and two studies that used the
same  group, showing the same results (in this case, only
the  ﬁrst publication was included). Finally, 12 papers were
approved  for data extraction (Fig. 1).
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Table 1 – Study design features of safety of HPV vaccines.
Author, year Local Follow-up Inclusion criteria Vaccine type Control Age interval n
Harper, 2004 Multicenter 27 months No more than six sexual partners;
no  history of an abnormal Pap test
or  ablative or excisional treatment
of  the cervix; no ongoing
treatment  for external
condylomata; cytologically
negative,  seronegative for HPV-16
and  HPV-18 antibodies by ELISA,
and  HPV-DNA-negative by PCR for
14 high-risk HPV types no more
than  90 days before study entry.
16/18  Aluminum
hydroxide.
15–25  1113
Bhatla, 2010 India 7 months Nonpregnant or planning to
become  pregnant; not taking any
other  investigational products or
steroids.
16/18 Aluminum
hydroxide.
18–35  354
Kim, 2010 Korea 7 months Nonpregnant or planning to
become  pregnant; not taking any
other  investigational products or
immune-modifying drugs and not
breastfeeding during the study.
16/18  Aluminum
hydroxide.
10–14  321
Medina, 2010 Multicenter 14 months Healthy girls. 16/18 Hepatitis A
virus  vaccine
12+-  2067
Ngan, 2010 Hong Kong 7 months Healthy women aged 18–35 years. 16/18 Aluminum
hydroxide.
18–35  294
Kim, 2011 Korea 7 months Nonpregnant and agreed to use
adequate  contraceptive
precautions over the vaccination
period.
16/18  Aluminum
hydroxide.
15–25  225
Szarewski, 2011 Multicenter 4 years Nonpregnant; no more than six
lifetime  sexual partners before
enrolment;  agreed to use adequate
contraception  over the vaccination
period  and had an intact cervix.
16/18  Hepatitis A
virus  vaccine.
15–25  18,644
Khatun, 2012 Bangladesh 16 months Unmarried and sexually
unexposed.
16/18  No vaccine. 9–13 67
Reisinger, 2007 Multicenter 18 months Nonpregnant; must not have had a
febrile illness (fever more than
37.8 ◦C [100 ◦F]) at vaccination.
6/11/16/18 Aluminum
hydroxide.
9–15  1781
Kang, 2008 Korea 7 months Nonpregnant; must not have had a
febrile illness (fever more than
37.8 ◦C [100 ◦F]) at vaccination;
subjects aged 9–15 years: no sexual
experience before and no plan to
have sexual experience during the
study period; subjects aged 16–23:
less  than four male and/or female
sexual  partners at enrollment and
were required to use effective
contraception  during the study
period.  Exclusion criteria:
enrollment  in studies of other
investigational  agents; any HPV
vaccination,  history of allergy to
vaccine compound;
thrombocytopenia; history of
vaccination  within 14 days from
enrollment;  receipt of blood or
blood-derived  products within the
6 months preceding injection, and
immunosuppression. Subjects
aged  16–23 years of age: have not
had a prior Pap test showing a
squamous  intraepithelial lesion or
worse and/or a biopsy indicating
CIN  or worse.
6/11/16/18 Same
adjuvant.
9–23  176
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Table 1 (Continued)
Author, year Local Follow-up Inclusion criteria Vaccine type Control Age interval n
Lazcano-Ponce,
2009
Mexico 48 months Nonpregnant; four or less sexual
partners  during their lifetime.
6/11/16/18  Aluminum
hydroxide.
18–23  679
Mun˜oz,  2009 Multicenter 48 months Nonpregnant; no history of genital
warts  or present or past; not
immunocompromised (HIV or
other),  not undergone
hysterectomy; required to use
effective  contraception until
month  7 of the study. Women with
any previous cervical surgical
procedure  and those having
undergone  a cervical biopsy within
the past 5 years were excluded.
6/11/16/18  Aluminum
hydroxide.
24–45  3819
Table 2 – Meta-analysis of HPV side effects.
Outcome Studies Doses Vaccine type Effect estimate
Pain 6 9427 16/18 3.29 [3.00, 3.60]
Fatigue 5 9082 16/18 1.29 [1.18, 1.42]
Redness 5 9133 16/18 2.41 [2.17, 2.68]
Swelling 5 9133 16/18 3.14 [2.79, 3.53]
Fever 4 8788 16/18 1.21 [1.03, 1.42]
GI symptoms 4 8788 16/18 1.13 [1.00, 1.28]
Headache 4 8788 16/18 1.17 [1.06, 1.28]
Myalgia 4 8013 16/18 1.97 [1.77, 2.20]
Arthralgia 3 7719 16/18 1.40 [1.20, 1.64]
Local symptoms 2 1363 16/18 2.33 [1.61, 3.36]
General symptoms 2 1414 16/18 1.07 [0.82, 1.41]
Pain 3 2580 6/11/16/18 2.88 [2.42, 3.43]
Swelling 2 2404 6/11/16/18 2.65 [2.04, 3.44]
General symptoms 4 6358 6/11/16/18 1.11 [1.00, 1.23]
Statistical method was Odds Ratio (M-H, Fixed, 95% CI).
Table 3 – Meta-analysis of adverse events associated with HPV 6/11/16/48 and HPV 16/18 vaccines.
Outcome n HPV 6/11/16/18 (experimental group) n HPV 16/18 (control group) Total Effect estimate
Pain 1608 4818 6426 0.97 [0.85, 1.11]
Swelling 1491 4670 6161 1.38 [1.20, 1.59]
Fever 579 4499 5078 1.19 [0.84, 1.68]
Local symptoms 1889 679 2568 4.08 [2.98, 5.59]
General symptoms 3498 702 4200 4.37 [3.64, 5.24]
 vaccStatistical method was Odds Ratio (M-H, Fixed, 95% CI). HPV 6/11/16/18
group.
Data  extraction
Various study characteristics were extracted from the original
research  and included in the meta-analysis. The data included
the  ﬁrst authors’ last names, year of publication, place of the
study,  follow-up period, inclusion/exclusion criteria, type of
vaccine  used, type of control used, and age interval (Table 1).
Analysis
Data were  entered in the Review Manager software (RevMan
245.2), which allows the user to enter protocols as well as com-
plete  reviews, including text, features of studies, comparison
tables,  and study data, as well as to perform meta-analysis of
the  entered data. Odds Ratios were obtained.ine was considered the control group and HPV 16/18 the experimental
Results
Twelve reports of HPV vaccine safety and AE involving 29,540
subjects  were included. The design features of the clinical
trials  to assess safety of the chosen HPV vaccines are indi-
cated  in Table 1. Eight studies17,18,25–30 evaluated HPV 16/18
vaccines, including 23,085 subjects; two studies18,30 approved
for  systematic review were not included in the meta-analysis
as  they did not compare data from experimental and control
groups.  Four studies16,31–33 including 6455 subjects evaluated
HPV 6/11/16/18 vaccine (Table 1).
Tables 2 and 3 show a summary of the main AE. The
most common AE seen with HPV 16/18 vaccine were,  in
this  sequence: pain, fatigue, redness, swelling, fever, GI
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Study
Pain
Redness
Swelling
Fever
Local symptoms
Bhatla, 2010 137 171 105 174 4.0% 2.65 [1.63, 4.29]
Harper, 2004 496 531 468 538 5.9% 2.12 [1.39, 3.24]
Kim, 2010 286 474 147 483 11.1% 3.48 [2.66, 4.54]
Kim, 2011 381 429 139 210 4.0% 4.05 [2.68, 6.14]
Medina, 2010 2150 3065 1263 3058 72.4% 3.34 [3.00, 3.71]
Ngan, 2010 126 148 91 146 2.6% 3.46 [1.97, 6.08]
Subtotal (95% CI)  4818  4609 100.0% 3.29 [3.00, 3.60]
Total events 3576  2213
Heterogeneity: Chi2=6.14, df=5 (P=.29); I2=19%
Test for overall effect: Z=25.79 (P<.00001)
Bhatla, 2010 56 171 24 174 3.5% 3.04 [1.78, 5.20]
Harper, 2004 189 531 131 538 18.1% 1.72 [1.32, 2.24]
Kim, 2010 119 474 54 483 8.6% 2.66 [1.87, 3.78]
Kim, 2011 381 429 139 210 4.5% 4.05 [2.68, 6.14]
Medina, 2010 850 3065 418 3058 65.3% 2.42 [2.13, 2.76]
Subtotal (95% CI)  4670  4463 100.0% 2.41 [2.17, 2.68]
Total events 1595  766
Heterogeneity: Chi2=13.37, df=4 (P=.010); I2=70%
Test for overall effect: Z=16.46 (P<.00001)
Bhatla, 2010 70 171 35 174 6.1% 2.75 [1.70, 4.45]
Harper, 2004 182 531 113 538 22.0% 1.96 [1.49, 2.58]
Kim, 2010 99 474 27 483 6.3% 4.46 [2.85, 6.97]
Kim, 2011 171 429 25 210 6.0% 4.90 [3.10, 7.77]
Medina, 2010 721 3065 261 3058 59.6% 3.30 [2.83, 3.84]
Subtotal (95% CI)  4670  4463 100.0% 3.14 [2.79, 3.53]
Total events 1243  461
Heterogeneity: Chi2=17.97, df=4 (P=.001); I2=78%
Test for overall effect: Z=18.99 (P<.00001)
Harper, 2004 88 531 73 538 23.1% 1.27 [0.90, 1.77]
Kim, 2010 13 474 7 483 2.6% 1.92 [0.76, 4.85]
Kim, 2011 7 429 2 210 1.0% 1.73 [0.36, 8.38]
Medina, 2010 239 3065 208 3058 73.3% 1.16 [0.96, 1.41]
Subtotal (95% CI)  4499  4289 100.0% 1.21 [1.03, 1.42]
Total events 347  290
Heterogeneity: Chi2=1.40, df=3 (P=.71); I2=0%
Test for overall effect: Z=2.27 (P=.02)
Harper, 2004 499 531 472 538 71.2% 2.18 [1.40, 3.39]
Ngan, 2010 133 148 112 146 28.8% 2.69 [1.39, 5.19]
Subtotal (95% CI)  679  684 100.0% 2.33 [1.61, 3.36]
Total events 632  584
Heterogeneity: Chi2=0.27, df=1 (P=.60); I2=0%
Test for overall effect: Z=4.53 (P<.00001)
Weight
Odds ratio
M-H, Fixed, 95% CI
Odds ratio
 M-H, Fixed, 95% CI
Vaccine
Events Total
Control
Events Total
0.1 0.2 0.5 1 2 5 10
Favours vaccine Favours control
/18 v
s
a
cFig. 2 – Meta-analysis of HPV 16ymptoms (diarrhea, nausea, vomiting), headache, myalgia
nd  arthralgia. The global Odds Ratios (M-H, Fixed, 95% CI –
alculated  after meta-analysis) compared to their respectiveaccines’ side effects (part one).control  groups are shown in Table 2. Three studies17,25,27 sep-
arated  their results as general symptoms and injection-site
symptoms; each was  analyzed separately. The injection-site
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Study
Fatigue
Gl symptoms
Headache
Myalgia
Arthralgia
General symptoms
Bhatla, 2010 65 171 61 174 37.3% 1.14 [0.73, 1.76]
Harper, 2004 458 531 462 538 62.7% 1.03 [0.73, 1.46]
Subtotal (95% CI)  702  712 100.0% 1.07 [0.82, 1.41]
Total events 523  523
Heterogeneity: Chi2=0.11, df=1 (P=.74); I2=0%
Test for overall effect: Z=.49 (P=.62)
Harper, 2004 308 531 289 538 15.1% 1.19 [0.93, 1.52]
Kim, 2010 90 474 87 483 8.8% 1.07 [0.77, 1.48]
Kim, 2011 210 429 69 210 5.9% 1.96 [1.39, 2.77]
Medina, 2010 893 3065 752 3058 67.0% 1.26 [1.13, 1.41]
Ngan, 2010 65 148 45 146 3.2% 1.76 [1.09, 2.84]
Subtotal (95% CI)  4647  4435 100.0% 1.29 [1.18, 1.42]
Total events 1566  1242
Heterogeneity: Chi2=9.15, df=4 (P=.06); I2=56%
Test for overall effect: Z=5.42 (P<.00001)
Harper, 2004 178 531 172 538 24.3% 1.07 [0.83, 1.39]
Kim, 2010 24 474 33 483 6.6% 0.73 [0.42, 1.25]
Kim, 2011 75 429 17 210 4.0% 2.41 [1.38, 4.19]
Medina, 2010 382 3065 346 3058 65.0% 1.12 [0.96, 1.30]
Subtotal (95% CI)  4499  4289 100.0% 1.13 [1.00, 1.28]
Total events 659  568
Heterogeneity: Chi2=9.85, df=3 (P=.02); I2=70%
Test for overall effect: Z=1.95 (P=.05)
Harper, 2004 331 531 329 538 15.7% 1.05 [0.82, 1.35]
Kim, 2010 62 474 76 483 8.4% 0.81 [0.56, 1.16]
Kim, 2011 127 429 43 210 5.2% 1.63 [1.10, 2.42]
Medina, 2010 891 3065 778 3058 70.7% 1.20 [1.07, 1.34]
Subtotal (95% CI)  4499  4289 100.0% 1.17 [1.06, 1.28]
Total events 1411  1226
Heterogeneity: Chi2=7.74, df=3 (P=.05); I2=61%
Test for overall effect: Z=3.17 (P=.002)
Kim, 2010 26 474 18 483 6.1% 1.50 [0.81, 2.77]
Kim, 2011 46 429 9 210 3.9% 2.68 [1.29, 5.59]
Medina, 2010 369 3065 283 3058 90.0% 1.34 [1.14, 1.58]
Subtotal (95% CI)  3968  3751 100.0% 1.40 [1.20, 1.64]
Total events 441  310
Heterogeneity: Chi2=3.32, df=2 (P=.19); I2=40%
Test for overall effect: Z=4.32 (P<.00001)
Kim, 2010 79 474 40 483 7.0% 2.21 [1.48, 3.32]
Kim, 2011 189 429 54 210 8.6% 2.27 [1.58, 3.27]
Medina, 2010 890 3065 522 3058 78.6% 1.99 [1.76, 2.25]
Ngan, 2010 37 148 36 146 5.8% 1.02 [0.60, 1.73]
Subtotal (95% CI)  4116  3897 100.0% 1.97 [1.77, 2.20]
Total events 1195  652
Heterogeneity: Chi2=6.92, df=3 (P=.07); I2=57%
Test for overall effect: Z=12.24 (P<.00001)
Weight
Odds ratio
M-H, Fixed, 95% CI
Odds ratio
 M-H, Fixed, 95% CI
Vaccine
Events Total
Control
Events Total
0.1 0.2 0.5 1 2 5 10
Favours vaccine Favours control
Fig. 3 – Meta-analysis of HPV 16/18 vaccine side effects (part two).
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Study
Pain
Swelling
General symptoms
Kang, 2008 84 117 30 59 7.6% 2.46 [1.28, 4.71]
Lazcano-Ponce, 2009 256 326 223 329 28.2% 2.06 [1.44, 2.97]
Reisinger, 2007 853 1165 265 584 64.2% 3.29 [2.67, 4.05]
Subtotal (95% CI)  1608  972 100.0% 2.88 [2.42, 3.43]
Total events 1202  518
Heterogeneity: Chi2=5.05, df=2 (P=.08); I2=60%
Test for overall effect: Z=11.93 (P<.00001)
Lazcano-Ponce, 2009 69 326 40 329 39.8% 1.94 [1.27, 2.96]
Reisinger, 2007 241 1165 45 584 60.2% 3.12 [2.23, 4.37]
Subtotal (95% CI)  1491  913 100.0% 2.65 [2.04, 3.44]
Total events 310  85
Heterogeneity: Chi2=3.00, df=1 (P=.08); I2=67%
Test for overall effect: Z=7.32 (P<.00001)
Castellsague, 2011 746 1890 697 1888 62.2% 1.11 [0.98, 1.27]
Kang, 2008 14 117 4 59 0.7% 1.87 [0.59, 5.95]
Lazcano-Ponce, 2009 101 326 96 329 9.7% 1.09 [0.78, 1.52]
Reisinger, 2007 541 1165 260 584 27.4% 1.08 [0.88, 1.32]
Subtotal (95% CI)  3498  2860 100.0% 1.11 [1.00, 1.23]
Total events 1402  1057
Heterogeneity: Chi2=0.86, df=3 (P=.83); I2=0%
Test for overall effect: Z=1.93 (P=.05)
Weight
Odds ratio
M-H, Fixed, 95% CI
Odds ratio
 M-H, Fixed, 95% CI
Vaccine
Events Total
Control
Events Total
0.1 0.2 0.5 1 2 5 10
Favours vaccine
Test for subqroup differences: Chi2=105.15, df=2 (P<.00001), I2=98.1% Favours control
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vents most related to the bivalent vaccine were  pain (OR 3.29;
5%  CI: 3.00–3.60), swelling (OR 3.14; 95% CI: 2.79–3.53), and
edness  (OR 2.41; 95% CI: 2.17–2.68). GI symptoms and gen-
ral  symptoms did not appear to be vaccine related (OR 1.13;
5%  CI: 1.00–1.28 and OR 1.07; 95% CI: 0.82–1.41 respectively)
Table 2 and Figs. 2 and 3).
With  the HPV 6/11/16/18 vaccine, fewer AE were reported
ecause only four papers were  ultimately approved. AE were
eneral  symptoms, pain, and swelling (Table 2). Again, gen-
ral  symptoms did not appear to be vaccine related. Pain
nd  swelling, however, were  vaccine related: OR 2.88; 95% CI:
.42–3.43 and OR 2.65; 95% CI: 2.0–3.44, respectively (Table 2
nd  Fig. 4).
It  was  possible to perform a meta-analysis comparing HPV
/11/16/18  and HPV 16/18 vaccines. The statistical method
as  again Odds Ratio (M-H, Fixed, 95% CI) considering HPV
/11/16/18  vaccine as control group and HPV 16/18 as experi-
ental  group. Thus, HPV 6/11/16/18 vaccine appears to be less
ssociated with swelling, fever, and general symptoms than
he  HPV 16/18 (Table 3). Fever was  not associated to any of the
accines.iscussion
dministration of HPV vaccine has been well tolerated in
ifferent  groups. The proportion of subjects reporting AE or1/16/18 vaccine side effects.
discontinuing  due to an AE is low and similar for the two
vaccines.
Occurrence of AE was  reported in all randomized control
trials.16–18,25–33 As anticipated, the most commonly reported
AE were  injection-site reactions16–18,25–33; most of these AE
were mild or moderate in intensity. These AE were  more  com-
mon  among those who received HPV vaccines when compared
with  placebo subjects. Headache and fatigue were  the most
common  vaccine-related systemic AE seen in approximately
50–60% of all participants.25–30 On the other hand, most of
these  AE were  mild or moderate in intensity.16–18,25–33 Simi-
larly to another study,34 serious vaccine related AE were  not
signiﬁcantly different, and there were no registered vaccine
related  deaths in all studies.16–18,25–34
On the other hand, a very recent systematic review also
reported barriers to preventive human papillomavirus vacci-
nation  among adolescent girls and young women: 21 barriers
to  vaccination were  identiﬁed. Cost was  the most frequently
reported barrier, followed by beliefs that vaccination was
unnecessary, and concerns regarding vaccine safety and side
effects.35
Recently an interesting cohort study conducted in Den-
mark  and Sweden identiﬁed no safety signals with respect
to  autoimmune, neurological and venous thromboembolic
adverse events after immunization of adolescent girls
with  quadrivalent human papillomavirus vaccine. In this
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multicenter study, 997,585 girls aged 10–17 were approached
from  whom 296,826 received a total of 696,420 quadrivalent
HPV (qHPV) vaccine doses. In this research, incident hospital
diagnosed  autoimmune, neurological or venous thromboem-
bolic  events (53 different outcomes) up to 180 days after each
qHPV  vaccine dose was  observed. There was  no association
between exposure to qHPV vaccine and venous thromboem-
bolism (RR 0.86; 95% CI 0.55–1.36). Regarding neurological
events, the relative risk for ﬁve occurrences were  not signif-
icantly  increased, and there were  inverse associations with
epilepsy  (RR 0.66; 95% CI 0.54–0.80) and paralysis (RR 0.56; 95%
CI  0.35–0.90). However, with respect to autoimmune events
exposure  to qHPV vaccine was  signiﬁcantly associated with
Behcet’s  syndrome (RR 3.37; 95% CI 1.05–10.80), Raynaud’s dis-
ease  (RR 1.67; 95 CI 1.14–2.44), and type 1 diabetes (RR 1.29; 95%
CI  1.03–1.62). These ﬁndings corroborate those from a cohort
study  of 189,629 women  in two managed care organizations in
California, who  found no safety signal when investigating the
risk  of 16 autoimmune events.15 That study did ﬁnd an inverse
association between exposure to qHPV vaccine and type 1 dia-
betes (RR 0.57; 95% CI 0.47–0.73), lending further support to the
conclusion  that the initial signal for type 1 diabetes that was
seen  in our study might be a false positive.36
Nevertheless, our results and the latter ﬁndings need to be
conﬁrmed  in studies with longer follow-up time, validation of
results,  and data on time of onset of disease. Further monitor-
ing  of HPV vaccine safety is warranted in other populations
where use and coverage have increased.
Despite these interesting data, there are several limitations
to  the evidence presented here. The heterogeneity of studies
associated  with methodological diversity would indicate that
the  studies suffer from different degrees of bias that prevented
the  conducting of a meta-analysis. Concerning AE, more  stud-
ies  evaluating both vaccines are still necessary.
Nonetheless, safety is not a major barrier to vaccination.
The cost of vaccines is still the main limiting factor for their
use  in developing countries.
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